Physician profile
Manuel Canga
NPI 1194770941
$7,434.26
in general payments reported to CMS, 2019-2025
29 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $773 · 2021: $775 · 2022: $1,417 · 2023: $815 · 2024: $1,440 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,284.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,484.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $884.67 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $859.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $734.56 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $503.28 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $423.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.58 | 2019-2025 | Jardiance, Ofev |
| Abbvie INC. | $212.70 | 2021-2024 | |
| Lilly USA, LLC | $166.28 | 2021-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $156.77 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $155.17 | 2019-2022 | |
| Abbott Laboratories | $75.33 | 2022 | |
| Astellas Pharma US INC | $63.23 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $62.63 | 2019-2022 | |
| Allergan, INC. | $57.23 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.14 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $37.13 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $35.69 | 2019 | |
| Merck Sharp & Dohme LLC | $32.14 | 2019 | |
| Eisai INC. | $32.09 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $29.41 | 2020-2022 | |
| Verity Pharmaceuticals INC. | $17.94 | 2024 | Tlando |
| Biohaven Pharmaceuticals, INC. | $17.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.38 | 2022 | |
| Mylan Specialty L.P. | $16.52 | 2019 | |
| Akebia Therapeutics INC | $16.52 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.98 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.31 | 2024 | Caplyta |
| Mannkind Corporation | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Canga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.